RNF19A Antibody

What is the structural organization of RNF19A and which epitopes are most suitable for antibody generation?

RNF19A contains three highly conserved domains including two RING finger motifs and an IBR motif at its N terminus . When selecting antibodies, researchers should consider that different commercial antibodies target different regions:

• N-terminal epitopes (example sequence: IFSTNTSSDN GLTSISKQIG DFIECPLCLL RHSKDRFPDI MTCHHRSCVD)

• C-terminal regions

• Middle sections (AA 741-825)

The choice of epitope can significantly affect detection sensitivity in different applications, with N-terminal antibodies generally showing good reactivity across multiple species.

How does RNF19A expression vary between normal and cancerous tissues?

Expression patterns of RNF19A are tissue and cancer-type dependent:

This contradictory expression pattern suggests context-dependent regulation and functions of RNF19A in different cancers.

What are the optimal western blotting conditions for RNF19A detection?

For successful western blot detection of RNF19A:

• Sample preparation: Use RIPA buffer containing 1% protease inhibitor (PMSF) and a cocktail for protein extraction .

• Protein loading: Load approximately 20 μg of protein per lane.

• Transfer: Use PVDF membranes for better protein retention.

• Blocking: Block with non-fat milk for 1 hour at room temperature.

• Primary antibody:

  • Concentration: 0.04-0.4 μg/mL for immunoblotting

  • Incubation: Overnight at 4°C

• Secondary antibody: Incubate for 2 hours at room temperature.

• Detection: Use chemiluminescence for visualization.

• Controls: Include GAPDH (1:10,000 dilution) as loading control .

This protocol has been validated in multiple cancer cell lines including NSCLC cell lines (A549, H292, H460, H661, H1299, and SK-MES-1) and BCa cell lines (UM-UC-3, J82, SW780, T24, and 5637).

How can I study RNF19A-mediated ubiquitination in experimental models?

To analyze RNF19A-mediated ubiquitination:

• In vivo ubiquitination assay:

  • Transfect HEK-293T cells with required plasmids (Flag-RNF19A, HA-target protein, His-Ub)

  • After 36 hours, treat cells with MG132 (10 μM) for 6 hours

  • Lyse cells with IP lysis buffer

  • Immunoprecipitate using HA- or Flag-tag magnetic beads

  • Wash beads with IP lysis buffer

  • Boil in SDS loading buffer

  • Detect ubiquitinated proteins via immunoblotting

• Protein stability assessment:

  • Perform cycloheximide (CHX) chase assay using 20 μg/ml CHX

  • Collect samples at 0, 2, 4, and 8 hours

  • Analyze protein degradation kinetics by western blot

  • Compare half-life between control and RNF19A-overexpressing or knockdown conditions

This approach has successfully demonstrated that RNF19A shortens the half-life of target proteins like p53 and ILK through ubiquitin-mediated degradation.

Why does RNF19A exhibit opposing roles in different cancer types and how can I reconcile this in my research?

The contradictory roles of RNF19A in different cancers relate to its substrate specificity:

To reconcile these differences in your research:

• Always validate RNF19A expression in your specific cancer model

• Identify the relevant substrate(s) in your system through IP-MS

• Consider RNF19A as part of a broader network rather than in isolation

• Examine multiple potential targets simultaneously

• Account for tissue-specific factors that might influence RNF19A function

What technical considerations are important when studying RNF19A-protein interactions?

For robust protein-protein interaction studies with RNF19A:

• Co-immunoprecipitation protocol:

  • Extract proteins using IP lysis buffer

  • Pre-clear with Protein A/G magnetic beads (20 μl) for 4 hours

  • Incubate supernatants with target antibody overnight at 4°C

  • Add 50 μl of Protein A/G beads for 2 hours

  • Wash beads three times with IP lysis buffer

  • Analyze by immunoblotting

• Critical controls:

  • Use IgG as negative control

  • Include both forward and reverse IP (RNF19A pulling target and target pulling RNF19A)

  • Validate with multiple antibodies targeting different epitopes

  • Include RNF19A mutants lacking E3 ligase activity (e.g., RNF19A-CA mutant)

• Avoiding false negatives:

  • Use proteasome inhibitors (MG132) to prevent degradation of ubiquitinated substrates

  • Consider transient vs. stable interactions (crosslinking might be necessary)

  • Test interactions under various cellular stress conditions (DNA damage, oxidative stress)

How can I optimize immunohistochemical detection of RNF19A in cancer tissues?

For optimal IHC staining of RNF19A:

• Antibody selection: Use antibodies validated for IHC (dilution 1:20-1:50 for Prestige Antibodies or 1:200-1:500 for other commercial antibodies )

• Antigen retrieval: Heat-induced epitope retrieval is essential for RNF19A detection

• Detection system: Use highly sensitive detection systems like DAB for chromogenic detection

• Controls and validation:

  • Include positive control tissues with known RNF19A expression

  • Use normal adjacent tissue as internal negative/reference control

  • Consider dual staining with cell-type specific markers

• Scoring system: Implement a standardized scoring system based on:

  • Staining intensity (0, 1+, 2+, 3+)

  • Percentage of positive cells

  • Subcellular localization

In clinical studies, RNF19A expression has been associated with tumor size (P < 0.05) and TNM stage (P < 0.05) in NSCLC patients, making proper quantification crucial .

What strategies can I use to overcome inconsistent results when studying RNF19A?

When facing inconsistent results with RNF19A experiments:

• Check antibody specificity:

  • Validate with RNF19A knockdown/knockout controls

  • Test multiple antibodies targeting different epitopes

  • Consider the isoform specificity of your antibody

• Cell line considerations:

  • RNF19A expression varies substantially between cell lines

  • In NSCLC, RNF19A is elevated in tumor cell lines compared to normal bronchial epithelial cells

  • In bladder cancer, RNF19A shows lower expression in cancer cell lines compared to normal urothelial cells

• Technical optimizations:

  • Standardize lysis conditions (consider detergent strength)

  • Optimize protein extraction from nuclear fractions

  • Implement rigorous quantification methods with appropriate normalization

• Biological variables:

  • Consider cell confluence effects on RNF19A expression

  • Account for stress responses that might alter RNF19A activity

  • Test under different growth factor conditions

How can I effectively use RNF19A as a prognostic or predictive biomarker in cancer research?

To utilize RNF19A as a cancer biomarker:

What experimental approaches should I use to explore novel RNF19A substrates?

To identify and validate new RNF19A substrates:

• Discovery approaches:

  • IP-MS following RNF19A overexpression

  • Ubiquitinome analysis comparing wild-type vs. RNF19A knockout cells

  • Protein stability profiling after RNF19A manipulation

• Validation workflow:

  • Direct interaction testing (co-IP, proximity ligation assay)

  • Ubiquitination assays with wild-type and catalytically inactive RNF19A mutants

  • Half-life determination using cycloheximide chase experiments

  • Ubiquitination site mapping through mass spectrometry

• Functional relevance:

  • Rescue experiments with ubiquitination-resistant mutants

  • Pathway analysis of identified substrates

  • Phenotypic assays related to substrate function

Studies have successfully identified multiple RNF19A substrates including p53 in NSCLC , ILK in bladder cancer , and BARD1 in the context of DNA damage repair , demonstrating the diverse targeting capacity of this E3 ligase.

How can I investigate the role of RNF19A in DNA damage response pathways?

To study RNF19A in DNA damage response:

• Focus on key interactions:

  • RNF19A has been shown to ubiquitinate BARD1, preventing BRCA1-BARD1 complex formation

  • This inhibits homologous recombination repair and sensitizes cells to PARP inhibitors

• Experimental approaches:

  • Measure γ-H2AX foci formation at different time points after DNA damage

  • Analyze chromosomal breaks in metaphase spreads

  • Employ dual reporter assays for simultaneous measurement of HR and NHEJ

  • Track recruitment of repair proteins (BRCA1/BARD1, RPA32, RAD51) to damage sites

• Therapeutic implications:

  • Test sensitivity to DNA damaging agents (Olaparib, Cisplatin, ionizing radiation)

  • Compare wild-type vs. RNF19A-deficient or overexpressing cells

  • Evaluate combinations of RNF19A modulation with established DNA damage repair inhibitors

This emerging area connects RNF19A to DNA repair mechanisms beyond its established roles in protein quality control and neurodegeneration .

What is the relationship between RNF19A and other E3 ligases in regulating cellular processes?

To investigate RNF19A in the context of the broader E3 ligase network:

• E3 ligase profiling:

  • RNF19A belongs to the ring between ring fingers (RBR) E3 ligase family

  • Compare substrate specificity with other RBR family members

  • Investigate potential compensatory mechanisms among related E3 ligases

• Cooperative and competitive interactions:

  • Test for synergistic or antagonistic effects with other E3 ligases

  • Investigate potential cross-regulation between E3 ligases

  • Map shared and unique substrates

• Context-dependent regulation:

  • Examine how cellular stress modulates the relative importance of different E3 ligases

  • Consider tissue-specific regulatory networks

  • Analyze developmental or differentiation stage-specific roles

Understanding RNF19A within the broader E3 ligase landscape will provide insight into the complexity of ubiquitin-mediated regulation in normal physiology and disease.